Study of Efficacy & Safety of Oral YM087 in Subjects With Euvolemic or Hypervolemic Hyponatremia

A 5-Day, Double-Blind, Placebo-Controlled Multicenter Study of Oral YM087 (CI-1025) to Assess Efficacy and Safety in Patients With Euvolemic or Hypervolemic Hyponatremia

Study of efficacy & safety of oral YM087 in subjects with euvolemic or hypervolemic hyponatremia

Inclusion Criteria:

• Serum Sodium 115 to <130mEq/L
• Plasma Osmolarity <290 mOsmol/kg H2O

Exclusion Criteria:

• Significant renal insufficiency
• Serum sodium increase of ≥8 mEq/L over the baseline day ( Hours 0 to 12)